Investigation Commenced Against CorMedix Inc. by Levi & Korsinsky
New York, NY – March 26, 2025
Levi & Korsinsky, a leading securities law firm, has announced that it has commenced an investigation of CorMedix Inc. (CRMD) regarding potential securities laws violations. The investigation comes in the wake of CorMedix’s fourth quarter and full-year 2024 financial results.
Background on CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company specializing in the development of antimicrobial therapeutics for the prevention and treatment of cardio-renal and respiratory infections. The company’s lead product candidate, PREVECAN, is an antimicrobial-coated central venous catheter (CVC) utilized for the prevention of catheter-related bloodstream infections (CRBSI).
Financial Results and Investor Reaction
On March 10, 2025, CorMedix reported its fourth quarter and full-year 2024 financial results, which showed a net loss of $35.6 million for the year, compared to a net loss of $25.3 million in 2023. The company also reported a cash burn rate of approximately $13.2 million per quarter.
Following the financial results announcement, CorMedix’s stock price dropped significantly, leading to substantial losses for investors. Levi & Korsinsky is investigating whether CorMedix and certain of its officers or directors may have issued false and/or misleading statements or failed to disclose material information.
Effects on Individual Investors
If you invested in CorMedix Inc. (CRMD) securities between certain dates, you may have valid claims and be eligible to participate in the investigation. If the investigation reveals securities laws violations, investors may be able to recover their losses through a securities class action lawsuit.
- If you suffered losses in CorMedix Inc. (CRMD) securities between specific dates, you may be eligible to participate in the investigation.
- Contact Levi & Korsinsky to discuss your potential eligibility and learn more about the investigation.
Effects on the World
The investigation against CorMedix Inc. could have broader implications for the biopharmaceutical industry and the investment community as a whole. The outcome of the investigation may influence investor confidence in biotech companies, particularly those in the antimicrobial therapeutics sector.
Additionally, if it is determined that CorMedix and its executives violated securities laws, it could serve as a warning to other companies and executives to ensure full transparency and accuracy in their financial reporting.
Conclusion
Levi & Korsinsky’s investigation into CorMedix Inc. highlights the importance of accurate financial reporting and transparency in the biopharmaceutical industry. As the investigation unfolds, investors will be closely watching the developments and their potential impact on the industry and their investments.
If you invested in CorMedix Inc. securities and believe you may be eligible to participate in the investigation, contact Levi & Korsinsky to learn more about your potential claims and how to protect your investment.
